Navigation Links
Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
Date:10/31/2013

EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed endocrinologists and primary care physicians (PCPs), Janssen Pharmaceuticals' Invokana captures a small percentage of type 2 diabetes patient share, with significant increases expected six months from now. Currently, a majority of type 2 diabetes patients are using metformin (excluding fixed-dose combinations) and one-third of patients are treated with long-acting insulins such as Sanofi's Lantus or Novo Nordisk's Levemir.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO

The TreatmentTrends®: Type 2 Diabetes (U.S.) 2013 report also finds that, within the GLP-1 drug class, Novo Nordisk's Victoza is the patient share leader, followed by Bristol-Myers Squibb/AstraZeneca's Byetta/Bydureon (if these products are considered independently).

The report examines five products in development for the treatment of type 2 diabetes—Bristol-Myers Squibb/AstraZeneca's dapagliflozin, GlaxoSmithKline's albiglutide, Eli Lilly's dulaglutide, Novo Nordisk's Tresiba and Takeda's fasiglifam. After reviewing a product profile, surveyed endocrinologists indicated a higher mean interest level for the long-acting insulin Tresiba versus the SGLT-2 inhibitor dapagliflozin.

"The report focuses on physician perception of type 2 diabetes product satisfaction, attribute importance, product performance and sales representative frequency and performance," said BioTrends Research Group Director Rob Dubman. "For example, the study found that at least 40 percent of surveyed physicians have seen a sales representative in the past m
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
2. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
3. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
4. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
5. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
6. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
7. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
8. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
9. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
10. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
11. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... provider for the medical industries, announced today the expansion of its ... New York City . genae Americas was incorporated in 2011. ... centered in one of the highest concentrations of medical innovation and ... , President at genae Americas. "The expansion of genae from ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
(Date:10/1/2014)... SAN MARCOS, Texas , Oct. 1, 2014 ... that it is scaling volume production of photoactive ... solar power technologies . While offering numerous advantages ... difficulty of producing large quantities of quantum dots ... has until now kept them from commercial utilization ...
Breaking Medicine Technology:genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... Feb. 8, 2012   Resource Anesthesia , an anesthesia ... several new locations to its management portfolio. ... announced today that the company has added the following ... Specialty Hospital of Washington -- Hadley, 4601 Martin Luther ...
... MLAB ) today reported a 21 percent increase in revenue and ... quarter ended December 31, 2011. Highlights: ... ,000 Quarterly revenues increased 21% year over year to ... in the fiscal third quarter Quarterly non-GAAP diluted earnings ...
Cached Medicine Technology:Resource Anesthesia Adds Locations Under Management, Announces Addition of HealthStream LearningCenter® 2Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 2Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 3Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 4Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income 5
(Date:10/2/2014)... October 02, 2014 USARAD Holdings ... and telemedicine solutions provider including its SecondOpinions.com® division, ... have joined its Executive Team as President & ... Brent Backhaus, USARAD’s new President and COO, is ... of progressively responsible experience in commercial-, medical- and ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 Robins ... from the Associated Builders and Contractors (ABC) of ... at tonight’s banquet held at Sheraton Birmingham Hotel., ... Massachusetts, Healthcare $10 Million to $25 Million, Obelisk ... Dental Clinic, Federal Government $10 Million to $25 ...
(Date:10/2/2014)... Maureen Salamon HealthDay Reporter ... women with a neurotic personality style and prolonged stress ... new research suggests. Tracking 800 women over nearly ... most anxious, jealous and moody -- which they defined ... the risk of developing Alzheimer,s compared to women scoring ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... reduced by breast-feeding. Nor will delaying the introduction of a ... help prevent celiac disease. Those are the conclusions ... New England Journal of Medicine . The new ... celiac disease if mothers breast-feed their babies and introduce gluten ...
(Date:10/1/2014)... researchers from the University of Adelaide have developed a ... of a good outcome from treatment - from their ... on a range of factors, including clinical symptoms, cognitive ... in the patient,s blood. , Speaking in the lead ... University,s Head of Psychiatry , Professor Bernhard ...
Breaking Medicine News(10 mins):Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 2Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 3Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2
... , TUESDAY, Jan. 4 (HealthDay News) -- Nearly 60 ... victims of violence, abuse or crime in the past year. ... happened. Researchers led by David Finkelhor of the University ... parents of children up to 9 years old in 2008. More ...
... Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Common ... stem cell defect, a finding that could potentially lead ... study reveals. Researchers say they discovered that a ... stem cells turn into hair-producing progenitor cells. That defect, ...
... , TUESDAY, Jan. 4 (HealthDay News) -- The ... (arrhythmias) that can cause sudden death may be underestimated, ... healthy people without heart disease found detectable changes in ... to polluted air. The findings suggest that air ...
... Jan. 4 (HealthDay News) -- Levels of schooling may affect ... heart attack called acute ST-segment elevation myocardial infarction (STEMI), a ... of heart attack, STEMI occurs when the coronary artery is ... heart. In the new study, Dr. Rajendra H. ...
... Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Simply measuring ... how many years they have left. In fact, a ... older people,s future life span about as well as taking ... disease. Walking speed may not be a perfect window ...
... YORK (Jan. 4, 2011) Researchers have produced a lasting anti-cocaine ... bits of the common cold virus with a particle that mimics ... published Jan. 4 in the online edition of Molecular Therapy ... researchers say this novel strategy might be the first to offer ...
Cached Medicine News:Health News:Survey Finds Much Victimization of Children Goes Unreported 2Health News:Stem Cell Defect Might Help Spur Common Baldness 2Health News:Stem Cell Defect Might Help Spur Common Baldness 3Health News:Higher Education May Benefit Some Heart Attack Patients 2Health News:Fast Walkers May Have More Years Ahead of Them 2Health News:Fast Walkers May Have More Years Ahead of Them 3Health News:Vaccine blocks cocaine high in mice 2Health News:Vaccine blocks cocaine high in mice 3
... a broad selection of tip ... wide variety of ophthalmic procedures. ... packaged sterile, complete with a ... in the "off " position ...
... Accu-Temp Cauteries provide a broad ... cauterization in a wide variety ... use cautery is packaged sterile, ... to lock switch in the ...
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
Medicine Products: